UPenn Digestive and Liver Center
The mission of the UPenn Digestive and Liver Center is to unite investigators with interests in digestive and liver disease in the exploration of creative experimental approaches, as well as to stimulate others to enter these areas of research. The scientific focus of the Center revolves around host-environmental interactions in digestive and liver disease research from bench to bedside. The Center is divided into three thematic areas: Intestinal Biology, Liver Biology, and the Microbiome. Center resources include five biomedical research cores to support research in both model systems and human subjects, a pilot & feasibility program, and various enrichment activities including a weekly seminar series, liver and intestinal stem cell clubs, and an annual retreat.
If you would like to become a member, please submit the requested information enclosed in our membership application.
Announcements
Message from Our New Center Director, Ken Cadwell!
Dear Colleagues and Friends,
I am honored to step into the role of Director of the UPenn Digestive and Liver Center and to have the opportunity to serve such an accomplished community. As I begin this new chapter, I first want to express my deep gratitude to Dr. Gary Wu for his exceptional leadership and dedication over the years. Gary’s contributions have been instrumental in shaping the Center’s success, and I am delighted that he has graciously agreed to continue serving as a co-Associate Director alongside Dr. Becky Wells. I am lucky to have their guidance as we build on the strong foundation they have established and navigate the challenges that may arise during this politically volatile period.
This edition of our quarterly newsletter brings exciting updates, including the announcement of our pilot award winners. The selection process was highly competitive, with a remarkable number of outstanding applications. This is a testament to the innovative research happening across our community. Congratulations to the awardees; your work embodies the excellence we strive to foster.
You may also notice that we’ve simplified our name to the UPenn Digestive and Liver Center, a change intended to make our identity clearer and easier to remember while staying true to our mission.
In my new role, I am committed to supporting our excellent core services and promote community building through the many enrichment activities organized by the Center. I look forward to working with all of you to drive our Center’s continued growth and impact.
Warm regards, Ken
Grant Citation
Please cite the UPenn Digestive and Liver Center (P30DK050306) in all publications related to core usage.
NOT-DK-24-031: “Availability of Administrative Supplements to Broaden the NIDDK Clinical Research Workforce":
This administrative supplement is designed to broaden the clinical research workforce with a specific focus on research coordinators. The supplement will provide funds to hire, train and support clinical research coordinators for up to two years to improve the outreach, recruitment, and community engagement of NIDDK clinical research studies, leading to more transformative research.
NIDDK Strategic Plan for Research
To review the NIDDK Strategic Plan for Research, click here.
Check out this NIDDK Resource Website (dkNET): https://dknet.org/
dkNET is a search portal funded by NIDDK that helps researchers find research resources relevant to their research and keep up to date on new tools, services and mandates to support robust and reproducible science. Research resources include reagents, organisms, software tools, databases and services.
Latest Publications from Center Members
-
Incidence, Predictors, and Course of Hepatocellular Carcinoma Following Direct-Acting Antivirals Therapy in a Prospective Genotype-3 Predominant HCV Elimination Compensated Cirrhosis Cohort
Wednesday, August 19, 2026
CONCLUSION: DAAs achieved an SVR-12 rate exceeding 95% in genotype-3 predominant HCV-compensated cirrhosis, with and without HCC. Incidence of de novo HCC post SVR-12 was 985 per 100,000 person-years, and 60% had BCLC Stage A. Post-SVR LSM and ALBI score predicted risk of HCC. Our data argue for mandatory HCC surveillance under the NVHCP for all patients with HCV-cirrhosis in India.
-
Tumor-reactive LAG3+CD8+ T cells diverge into terminally exhausted cells and long-lived memory T cells
Tuesday, August 18, 2026
Chronic T cell stimulation in tumors and chronic viral infections leads to T cell exhaustion, a state of dysfunction. As LAG3 marks a prominent subset of exhausted T (TEX) cells in mid-to-late stage tumors, we generated a Lag3 lineage-tracing mouse model (Lag3iCreERT2Rosa26LSL-tdTomato) to fate map and characterize tumor-reactive LAG3+CD8+ TEX cells. In tumor-bearing mice, two distinct tumor-specific tdTomato+ CD8+ T cell subsets stratified by LAG3 surface expression (LAG3+tdT+ and LAG3-tdT+)...
-
A Measured Approach: The Use of Phosphatidylethanol (PEth) in Alcohol-Associated Liver Disease and Liver Transplantation
Monday, August 17, 2026
No abstract